Breast cancer is the most common neoplasm in women, accounting for 26 % of all cancers diagnosed annually, it is overall the second leading cause of cancer death (following lung cancer). In Egypt breast cancer constitutes 33 % of all female cancer and the median age is 46 years old, one decade younger than corresponding western countries. The incidence of breast cancer is highest among women of higher socioeconomic background. Also the incidence is higher among whites less common in black women. Most cancer patients are diagnosed sporadic and not associated with any clear familial predisposition 1 .
Original article

IntroductIon
Breast cancer is the most common neoplasm in women, accounting for 26 % of all cancers diagnosed annually, it is overall the second leading cause of cancer death (following lung cancer). In Egypt breast cancer constitutes 33 % of all female cancer and the median age is 46 years old, one decade younger than corresponding western countries. The incidence of breast cancer is highest among women of higher socioeconomic background. Also the incidence is higher among whites less common in black women. Most cancer patients are diagnosed sporadic and not associated with any clear familial predisposition 1 .
Breast cancer is not a single entity but instead comprises several biologically distinct subtypes.
Based on molecular profiles, breast cancers have been classified into four main subtypes: luminal subtype A, luminal subtype B, ERbB2 positive receptors (HER2 positive/ER negative) and TNBC 2, 3, 4 .
Triple-negative breast cancer (TNBC) is defined as a clinical entity referring to tumors that do not express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER2) accounting for approximately 15%-20% 5, 6 of breast cancers. TNBC has important clinical implications, because it is typically high grade, and exhibits a high rate of proliferation 7, 8 . In general, compared with other subtypes of breast cancer, TNBC has a less favorable clinical outcome in terms of the nature and likelihood of progression, availability of various treatment options, and survival 9, 10 .
Certain treatment strategies for breast cancer have effectively exploited tumor biology. For examples, hormonal therapies and trastuzumab (Herceptin) target ER and HER2, respectively. TNBC is not amenable to either of these approaches. Although several targeted approaches are currently under investigation in patients with TNBC, the current standard of treatment for these patients consists of cytotoxic therapies such as anthracyclines and taxanes 11, 12 .
TNBC has a poorer prognosis than other breast cancer subtypes, regardless of the stage of disease at diagnosis. TNBC is associated with diminished progression-free survival (PFS) and overall survival (OS) after surgery or after recurrence. The risk of distant recurrence within 5 years was significantly higher in patients with TNBC than in those with other subtypes 13, 14 . 
PAtIEntS And MEtHodS
treatment regimens:
Patients were grouped according to adjuvant treatment received into two groups namely Platinum based chemotherapy and Classic non-platinum chemotherapy e.g. Anthracycline based or taxanes based chemotherapy.
Statistical Analysis:
The endpoints in this study were disease free survival (DFS). DFS was calculated from the date of start of the primary therapy to the date of breast cancer recurrence, the date of death from any cause, or the date of last follow up. DFS as a function of the markers studied was estimated by the Kaplan-Meier method and the log-rank test was used to test for differences. Data were statistically described in terms of range, mean ± standard deviation (± SD), frequencies (number of cases) and percentages when appropriate. Survival analysis was done for the different outcome measures using Kaplan Maier statistics calculating the mean and median survival time for each group with their 95 % confidence interval (95%CI) and the corresponding survival graphs. Factors examined as a stepwise adjusted Kaplan Meier were age at presentation (missing, <35, 35 to 49, >50 years), T status (missing, TX, T1, T2, T3, T4), N status (missing,N0, N1, N2, N3), menopausal status (missing, postmenopausal, premenopausal), ER status (missing, negative, or positive), PR status (missing, negative, or positive), and HER2/neu status (missing, negative, or amplified). A plot of RFS Vs the mentioned factors were calculated and compared between the two groups. A probability value (P value) less than 0.05 was considered statistically significant. The 3-year disease-free survivals of the four subtypes were assessed in relation to the clinico-epidemiological features as shown in Table ( 3). Disease free survival after 3 years for each subtype was 87.8% for luminal A, 86% for luminal B, 69% for TN and 66% for HER2 (P=. 008) Fig. 2 .
The 2 & 3 year disease-free survival for TN patients (N= 31) who received adjuvant platinumbased chemotherapy was 81% & 46% respectively and for those who received adjuvant non-platinum (N=74) chemotherapy was 84% & 78% respectively (log rank P-value= 0.135) as shown in Fig. 3 . 
dIScuSSIon
In this study, breast cancer represented 31.4 % of total number of cancer cases presented to Kasr elaini centre of clinical oncology and nuclear medicine (NEMROCK) between 1st of January 2005 and 31th December 2010. That percentage is more than the percentage proved by one of our national retrospective studies done by Yasser et al. 15 in the period between 1997 and 1999 in NEMROCK as well as the international results 16 . This increase in the incidence in our study is due to the increase in the number of referred breast cancer cases to NEMROCK from other centers to receive radiotherapy either (palliative or adjuvant) and also to have a second opinion.
On comparing the results of tumour sizes at presentation for patients presented to NEMROCK in the current study with the study done by Yasser et al. 15 , it was observed that an increase in the early detected tumours T1 and T2 with decrease in the incidence of advanced detected tumours T3 and T4 which mostly due the increase in the awareness of Egyptian females by screening programs with the development and spread of that programs which enables early detection of breast cancer at its early stages.
In the whole studied group, it was observed that lymph node involvement was almost equally divided among the three nodal states (N0,N1 and N2) 15 . These results showed that almost two thirds of the patients are considered to be at high risk groups that lead to poorer outcome 17, 18 .
On studying the effect of hormonal receptor status we found that ER positive patients experienced higher DFS percentage that represents 90.2% when compared with ER negative patients 78.2%, also PR positive patients have higher 3 years DFS 90.0% when compared with PR negative patients 80.2%. That results are in agree with the results proved in the study done by (Dunnwald et al. 19 who compared patients with ER+/PR+ with other group of patients with different hormonal profiles {ER+/PR-, ER-/PR+, or ER-/PR-} and it achieved the best DFS and the last group of tumors {ER-/PR-} experienced higher risks of mortality and low DFS.
On studying the effect of HER 2 status on 3 years DFS, we detected that HER2 negative cases showed 3 years DFS 89.0% better than HER2 positive cases that showed 3 years DFS 75.2% but, with no statistical significance P= 0.21. That results are in agree with results of study done in Queen Elizabeth hospital by Tovey et al. 20 who detected that HER2 positive patients had 3-year breast cancer-specific survival rates of 68% compared with 96% for the HER2-negative group. This result is attributed to the aggressiveness of HER2 positive tumours when compared with HER2 negative tumours. Also HER2 positive cases didn't receive [trastuzumab] .
Comparing the 3 years DFS for all group of non TNBC and TNBC we detected a survival difference between both groups with better survival for non TNBC with P value = 0.012. That results are comparable with the results in the study done by Dent et al. 13 who proved that TNBC patients had an increased like hood of distant recurrence (33.9% for TN versus 20.4% for non TNBC) and death within 5 years of diagnosis.
We compared the 3 years DFS of the four groups and we found that HER2 over expressing followed by TNBC patients experienced the worst 3 years DFS than luminal subtypes represented 66.0% and 69.0%, respectively 6 . The explanation for that is due to the lack of the gene expression profiling to identify basal subtype markers{Ck 5/6, and epidermal growth factor receptor (EGFR)} to help us to differentiate the TNBC group into basal of (bad prognosis) and non basal of (good prognosis) subtypes. Also HER2 positive cases didn't receive trastuzumab.
We divided the TN patients in two arms. Arm I, patients received platinum based chemotherapy as an adjuvant treatment and they were 31 patients and arm II, patients received other non platinum classic chemotherapy as an adjuvant treatment and they were 74 patients. The DFS curves for both arms were close at 48 months ( 81% for arm I and 84% for arm II), however at 30 months the difference became very large being 46% for arm I and 78% for arm II and in spite of large numerical difference after 30 months there was no significance between both curves (log rank P-value = 0.135). This may be due the small difference till at least 24 months, the small sample size especially in arm I and short follow up period. concluSIon HER2 over expressing followed by TNBC patients experienced the worst 3 years DFS than luminal subtypes. No survival difference is detected between patients who received platinum based chemotherapy and other patients who received classical non-platinum chemotherapy protocol.
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